Related Experiment Video

Updated: May 12, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

ANP-NPRA signaling pathway--a potential therapeutic target for the treatment of malignancy

Zhilong Zhao1, Jia Zhang, Min Li

  • 1Department of Surgical Oncology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Critical Reviews in Eukaryotic Gene Expression
|April 16, 2013
PubMed

Insights

The atrial natriuretic peptide (ANP)/natriuretic peptide receptor-A (NPRA) pathway, known for cardiovascular regulation, also impacts cancer. Evidence suggests ANP and NPRA have anti-cancer roles, making this pathway a potential therapeutic target.

Area of Science:

  • Cardiovascular Biology
  • Oncology
  • Molecular Signaling

Background:

  • The atrial natriuretic peptide (ANP)/natriuretic peptide receptor-A (NPRA) pathway is established in cardiovascular regulation.
  • Emerging evidence highlights the ANP/NPRA pathway's significant role in human cancer.
  • NPRA is overexpressed in prostate cancer cells, and its downregulation induces apoptosis.

Purpose of the Study:

  • To review the structure and function of the ANP/NPRA signaling pathway.
  • To explore the pathway's regulation by cell signaling.
  • To summarize the pathway's diverse impacts on tumor development and progression.

Main Methods:

  • Literature review of existing studies on ANP/NPRA signaling in cardiovascular and cancer biology.
  • Analysis of data demonstrating NPRA expression in various cancer types.
  • Examination of studies investigating the effects of ANP/NPRA modulation on cancer progression and treatment.

Main Results:

  • NPRA is highly expressed in tumorigenic cells, including prostate cancer, but not in normal cells.
  • Downregulation of NPRA promotes apoptosis in prostate cancer cells.
  • NPRA deficiency confers protection against lung, skin, and ovarian cancers in mice.
  • Dexamethasone, used in multiple myeloma treatment, significantly increases ANP expression.

Conclusions:

  • ANP and NPRA may possess anti-cancer and anti-carcinogenesis properties, respectively.
  • The ANP/NPRA signaling pathway represents a promising therapeutic target for cancer treatment.
  • Further research into this pathway's role in oncology is warranted.

More Related Videos

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...